-
DE
Angiogenesis inhibition refers to the targeted suppression of new blood vessel formation. It is primarily used in cancer therapy to cut off the blood supply to tumors.
Angiogenesis inhibition refers to the targeted suppression of new blood vessel formation. It is primarily used in cancer therapy to cut off the blood supply to tumors.
Angiogenesis inhibition (also referred to as anti-angiogenesis or antiangiogenic therapy) is the deliberate blocking of angiogenesis – the process by which new blood vessels form from pre-existing ones. Under normal conditions, angiogenesis plays a vital role in wound healing and tissue growth. However, in pathological states such as cancer and certain eye diseases, uncontrolled blood vessel growth can be harmful. Angiogenesis inhibitors are drugs or substances that specifically target and block this process.
Beyond a certain size, tumors require their own blood supply to receive oxygen and nutrients. To achieve this, they secrete signaling proteins – most notably Vascular Endothelial Growth Factor (VEGF) – that stimulate the growth of new blood vessels. Without this vascular network, tumors cannot continue to grow or spread to other parts of the body (metastasis). Angiogenesis inhibition aims to block this critical step in tumor progression.
Angiogenesis inhibitors work through several mechanisms:
The most important application of angiogenesis inhibition is in cancer treatment. Angiogenesis inhibitors are often used in combination with chemotherapy or other targeted therapies. Approved indications include:
In eye care, anti-VEGF agents (e.g., ranibizumab, aflibercept) are used to treat wet age-related macular degeneration (AMD) and diabetic macular edema. By inhibiting pathological blood vessel growth in the retina, these drugs can slow or halt vision loss.
Because angiogenesis inhibitors also affect normal physiological vascular processes, a range of side effects can occur:
Research into angiogenesis inhibition remains an active and rapidly evolving field. Combination therapies pairing angiogenesis inhibitors with immune checkpoint inhibitors are showing promising results across multiple cancer types. Scientists are also investigating how to overcome resistance mechanisms that tumors develop against anti-angiogenic drugs, with the goal of improving long-term treatment outcomes.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.